Alvotech
ALVO

$11.15

0.72%

Market Cap: $3.36B

About: Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

Employees: 999

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

41% more funds holding

Funds holding: 22 [Q1] → 31 (+9) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

0.3% less ownership

Funds ownership: 5.65% [Q1] → 5.35% (-0.3%) [Q2]

2% less capital invested

Capital invested by funds: $182M [Q1] → $179M (-$3.13M) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$18

61%

upside

Avg. target

$18

61%

upside

High target

$18

61%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Barclays

Balaji Prasad

50% 1-year accuracy

18 / 36 met price target

61%upside

$18

Overweight

Maintained

25 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ALVO published over the past 30 days

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Members of the management team will hold an in-person fireside chat on September 5, 2024, starting at 5:35 pm EDT (21:35 GMT).

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Members of the management team will hold an in-person fireside chat on September 5, 2024, starting at 5:35 pm EDT (21:35 GMT).

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech: Steady Progress Offers A Good Chance Of Upside

Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million.

Alvotech: Steady Progress Offers A Good Chance Of Upside

Alvotech (ALVO) Q2 2024 Earnings Call Transcript

Alvotech (NASDAQ:ALVO ) Q2 2024 Earnings Conference Call August 16, 2024 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director, Investor Relations and Global Communications Robert Wessman - Founder, Chairman and Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Kirsty Ross Stewart - Citi Operator Good day, and thank you for standing by. Welcome to the Alvotech's Q2 2024 Earnings Conference Call.

Alvotech (ALVO) Q2 2024 Earnings Call Transcript

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

REYKJAVIK, Iceland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025.

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025.

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

REYKJAVIK, Iceland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the year ended June 30, 2024, after U.S. markets close on Thursday, August 15, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Friday August 16, 2024, at 8:00 am EDT (12 noon GMT).

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the year ended June 30, 2024, after U.S. markets close on Thursday, August 15, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Friday August 16, 2024, at 8:00 am EDT (12 noon GMT).

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

See News Rankings